Looking to the future with BBI’s new CEO, Mario Gualano

Looking to the future with BBI’s new CEO, Mario Gualano

What does the new headquarters mean for BBI and your customers?

BBI has come a long way since it began as a university spin-out 30 years ago with just a handful of staff. We now employ more than 500 people across 12 global sites spanning the UK, Europe, USA, Asia Pacific and South Africa. We realised back in 2017 that we’d outgrown our Cardiff site and needed a new headquarters.

The Crumlin site gives us the space we need to drive growth. It’s a 120,000 sq ft (36,500 sq m) footprint facility with state of the art laboratory and production areas and excellent road transport links to the M4 and Cardiff Airport. The improved manufacturing and production facilities, along with the investment we’re making at our other sites means we can support our long-term growth plans and support our customers’ future growth. Accreditation to ISO 13485:2016 means our customers can be assured that quality is at the heart of our processes. Bringing three former manufacturing sites under one roof offers a significant opportunity to drive the productivity of the business.

As our customers already know, our specialist, high-quality gold nanoparticles are renowned for offering exceptional levels of assay consistency, quality and reliability and are used in more than 400 million assays globally every year. It was exciting to see our first batch of gold from Crumlin go into production back in February, and now our manufacturing line is fully up and running.

The next stage in the process will be to move our enzyme production from Blaenavon to our new site. I am really looking forward to seeing our talented teams working together at our new global headquarters.

With the recent acquisition of Maine Biotechnology Services (MBS), BBI Solutions can offer a comprehensive lateral flow solution, to support clients all the way from antibody development to a mobile diagnostic reader app. The company is one of the first in the diagnostics market to offer this inclusive solution, encompassing the whole product journey, in-house.

It’s fantastic to be at the forefront of the IVD industry, driving innovation and growth to a growing global market. The investment in our facilities means we have the infrastructure to grow with our customers, and I am excited to see what the future will bring.

To view our range of products and services, visit us at www.bbisolutions.com

About Mario Gualano

Mario Gualano is Group CEO of the BBI Group, where he was previously Global Head of Commercial.

With more than 20 years’ experience in the microbiology and diagnostics industry, Mario has a wealth of commercial, technical and operational experience. He spent more than ten years with Thermo-Fisher Scientific in various operational and commercial roles, most recently as President of the Microbiology division, where he was responsible for 14 manufacturing sites and 30 commercial offices globally, totalling revenue of $550M.

Mario completed his first degree at Cardiff University and has a long association with south Wales. He has a PhD in Microbiology and Immunodiagnostics and an MBA from Henley.



Copyright © 2018 BBI Solutions. All rights reserved. Designed trademarks and brands are the property of their respective owners. BBIUS